Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Exelixis Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Exelixis Enters into Agreement with Roche 12
Exelixis Enters into Agreement with Bristol-Myers Squibb 13
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 14
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 16
Licensing Agreements 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 18
Ipsen Amends Licensing Agreement with Exelixis 19
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 20
Equity Offering 21
Exelixis Raises USD155 Million in Public Offering of Shares 21
Exelixis Completes Public Offering Of Shares For US$80 Million 22
Exelixis Completes Public Offering Of Common Stock For US$147 Million 23
Exelixis Completes Public Offering Of Common Stock For US$69 Million 24
Exelixis Completes An Underwritten Public Offering For US$190 Million 26
Debt Offering 28
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 28
Exelixis Inc – Key Competitors 30
Exelixis Inc – Key Employees 31
Exelixis Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 02, 2017: Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update 36
May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update 39
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Nov 03, 2016: Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update 46
Aug 03, 2016: Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update 49
May 04, 2016: Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update 52
Feb 29, 2016: Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 55
Corporate Communications 58
Sep 26, 2016: Exelixis Elects Julie Anne Smith to Its Board of Directors 58
Legal and Regulatory 59
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 59
Product News 60
12/07/2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline 60
10/16/2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 61
09/20/2016: Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress 63
09/14/2016: European Commission Approves Ipsens Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma In Adults Following Prior Vascular Endothelial Growth Factor (Vegf)-Targeted Therapy 64
07/22/2016: Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy 66
04/20/2016: Exelixis Announces Presentation On Cabozantinib At 2016 ASCO Annual Meeting 68
Product Approvals 70
Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 70
Aug 16, 2017: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX for the Treatment of Previously Untreated Advanced Kidney Cancer 72
Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients 74
Jul 10, 2017: Life-extending tablet for advanced kidney cancer, Cabometyx (cabozantinib), approved by NICE for routine access by English and Welsh patients 75
Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer 76
Mar 06, 2017: Exelixis’ Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma 77
Jan 28, 2016: Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 78
Jan 28, 2016: Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 79
Jan 11, 2016: Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 80
Clinical Trials 81
Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium 81
Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 82
Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 84
Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 85
Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 87
Sep 04, 2017: Ipsen To Present 7 Abstracts on Cabometyx at European Society of Medical Oncology congress 88
Aug 01, 2017: Exelixis to Feature Presentations on Cabozantinib at ESMO 2017 Congress 90
Jun 19, 2017: Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma 93
Jun 12, 2017: Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors 94
Jun 01, 2017: Ipsen To Present New Data of Cabometyx at ASCO 95
Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors 97
Oct 10, 2016: Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 99
Oct 07, 2016: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors 101
Sep 27, 2016: Ipsen Announces Data Presentations of Cabozantinib (Cabometyx) at the European Society for Medical Oncology (ESMO) 2016 Congress 102
Sep 06, 2016: Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma 104
Aug 31, 2016: Exelixis presents cabozantinib data at the ESMO 2016 Congress 105
Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 107
May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 109
Apr 25, 2016: Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 111
Feb 01, 2016: Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma 113
Jan 04, 2016: Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium 115
Other Significant Developments 117
Sep 07, 2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy 117
Appendix 118
Methodology 118
About GlobalData 118
Contact Us 118
Disclaimer 118
Exelixis Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Exelixis Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Exelixis Enters into Agreement with Roche 12
Exelixis Enters into Agreement with Bristol-Myers Squibb 13
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 14
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 16
Takeda Pharma Enters into Licensing Agreement with Exelixis 18
Ipsen Amends Licensing Agreement with Exelixis 19
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 20
Exelixis Raises USD155 Million in Public Offering of Shares 21
Exelixis Completes Public Offering Of Shares For US$80 Million 22
Exelixis Completes Public Offering Of Common Stock For US$147 Million 23
Exelixis Completes Public Offering Of Common Stock For US$69 Million 24
Exelixis Completes An Underwritten Public Offering For US$190 Million 26
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 28
Exelixis Inc, Key Competitors 30
Exelixis Inc, Key Employees 31
Exelixis Inc, Subsidiaries 32